Brought to you by 
Presidio grants Ascletis exclusive Chinese rights to PPI668 for HCV
02 Feb 2023
Executive Summary
Antivirals developer Presidio Pharmaceuticals Inc. licensed Ascletis Inc. (therapies for cancer and infectious diseases) exclusive rights to develop and commercialize PPI668 for hepatitis C in China.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Presidio grants Ascletis exclusive Chinese rights to PPI668 for HCV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice